SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 10,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $8.91, for a total transaction of $89,100.00. Following the sale, the insider owned 556,887 shares of the company’s stock, valued at $4,961,863.17. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $30,080.00.
• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total value of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total value of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total value of $38,221.81.

SOPHiA GENETICS Stock Up 3.2%

Shares of SOPH stock opened at $8.40 on Tuesday. SOPHiA GENETICS SA has a fifty-two week low of $3.10 and a fifty-two week high of $8.98. The firm has a market capitalization of $704.68 million, a PE ratio of -7.30 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The stock’s 50-day simple moving average is $6.58 and its 200-day simple moving average is $5.48.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. Equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC lifted its stake in shares of SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares during the period. Dimensional Fund Advisors LP boosted its holdings in SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after buying an additional 6,205 shares in the last quarter. Principal Financial Group Inc. grew its position in SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after buying an additional 9,800 shares during the period. First Dallas Securities Inc. acquired a new stake in SOPHiA GENETICS during the first quarter valued at $50,000. Finally, Squarepoint Ops LLC purchased a new position in SOPHiA GENETICS in the third quarter valued at $49,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analysts Set New Price Targets

SOPH has been the topic of a number of research reports. HC Wainwright increased their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, BTIG Research boosted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.